The present review summarizes the results of epidemiological studies and clinical trials assessing the skeletal effects of soy foods and soy dietary supplements.
Introduction
Estrogen plays a significant role in the skeleton. In most women, the marked drop in estrogen concentrations during menopause results in accelerated bone turnover and bone loss. Although estrogen therapy prevents menopausal bone loss and reduces the risk of fractures, evidence from the Women's Health Initiative suggests that estrogen can increase the risk of cardiovascular disease and, when combined with progestins, can increase the risk of breast cancer [1] . As a result, many menopausal women now seek 'natural' alternatives that would provide benefits comparable to those of estrogen but without its complications [2, 3] . Epidemiological studies have shown a lower incidence of cardiovascular disease, breast cancer, and fractures in women in Asia compared to white western women. It has often been suggested that this difference is due to the soy-rich diet consumed in Asian countries; the effects of soy protein on bone metabolism have been largely attributed to its phytoestrogen content. Based on those facts, the consumption of soy products by western women has increased significantly in the last decade.
Phytoestrogens are plant-derived estrogens that can bind to the estrogen receptor and have agonist, antagonist, or partial agonist/antagonist effects on the estrogen receptor. There are three main classes of phytoestrogens: isoflavones, lignans, and coumestans. Soybeans, the most widely used dietary source of phytoestrogens, are rich in the isoflavones genistein and daidzein. Soybeans contain significantly different amounts of isoflavones depending on the strain of soybean, the region where the crop is grown, and weather conditions. The method of isoflavone extraction and the type of food preparation also affect the isoflavone content of foods. Consequently, soy food intake can result in a varying response making epidemiological and clinical studies difficult to interpret. In addition, dietary supplements containing phytoestrogens and phytoestrogen-fortified foods are not regulated by the Food and Drug Administration (FDA). Products often contain significantly different amounts of isoflavones from what is stated on the label. Daidzein and genistein are hydrolyzed into their aglycone forms by intestinal bacteria. Daidzein is further metabolized into equol, a compound with higher estrogenic activity. As this conversion occurs in only 30% of humans, it has been suggested but never proven that equol is responsible for the large variability in results of clinical trials testing soy products [4] .
In vitro, isoflavones have been shown to stimulate osteoblastic activity by increasing DNA content [5] , as well as to inhibit tyrosine kinase, a factor involved in the regulation of osteoclastic activity [6] . Results from invitro studies, though not conclusive in establishing an exact mechanism, are highly suggestive of isoflavones having an impact on bone metabolism. Although soy isoflavones have been shown to prevent bone loss after ovariectomy in animal studies, it is not clear from the results of human studies whether phytoestrogens can protect against perimenopausal bone loss and fractures. This review summarizes the results of epidemiological studies and clinical trials assessing the skeletal effects of soy foods and soy dietary supplements. Although most intervention studies have utilized combinations of genistein and daidzein, a few have tested a single isoflavone, and others have also included soy protein.
Soy foods
In cross-sectional studies of women in China and Japan, but not in Korea, soy food intake had a modest but significant positive association with bone mineral density (BMD) only in postmenopausal women (Table 1) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . A prospective 4-year study on more than 24 000 Chinese women demonstrated a negative association between consumption of soy products and fracture risk, particularly in women in the first 10 years of menopause [12] . Women in the USA consume very small amounts of soy to produce an effect; cross-sectional studies have shown a positive association only in premenopausal Japanese women living in the USA [13, 14] . Few intervention studies have utilized soy foods. In Italian women, a 6-month intervention consisting of one serving of soy food daily failed to show any beneficial effect on BMD, although more than half of the participants did not comply with the diet [15] . In postmenopausal Danish women, two glasses of soymilk daily prevented lumbar spine bone loss over 2 years [16] . A small uncontrolled study on Iranian women showed a reduction in a urinary marker of bone turnover after 12 weeks of consuming foods prepared with Gorgan, the local soy variety, containing a daily isoflavone dose of 98 mg [17] . This small number of studies that utilized different soy foods containing various amounts of isoflavones in different populations produced varying results, precluding any generalization on the skeletal effects of soy foods.
Soy tablets
Considering the difficulty in changing dietary habits, most interventions with isoflavones in western populations have used tablets containing isoflavones extracted from soy protein and not soy foods. However, soy isoflavones ingested in conjunction with the protein in soy foods might have a different effect than that when isoflavones are ingested alone. Although daidzein and genistein are structurally similar to estrogen and bind to the estrogen receptor, their affinity to the receptor is significantly weaker than estrogen's [18] . Because both bind to estrogen receptor-a but genistein binds preferably to estrogen receptor-b, different studies have tested single isoflavones or both in various combinations (Table 2) [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Single isoflavone tablets
Two long-term placebo-controlled interventions using a single isoflavone (genistein 54 mg/day) showed positive results with increases in BMD (3-5% in femoral neck and lumbar spine) and corresponding changes in markers of bone turnover [18, 19] . However, a 6-week study did not demonstrate statistically significant changes in bone turnover markers when comparing genistein 90 mg/day to placebo, but the lack of positive findings may have been due to the short intervention time [20] .
Multiple isoflavone tablets
Among the studies providing tablets with various combinations of isoflavones derived from soy protein, seven were conducted on western women and seven in women in Asia (Table 2 ). Most were randomized controlled trials lasting 4 weeks to 3 years. The isoflavone doses were comparable among the eight positive and the seven negative studies [18-20,21 ,22-34] . About half of the trials, equally distributed among the positive and negative studies, provided calcium supplements in addition to the isoflavone tablets.
The longest trial found a protective effect of high-dose isoflavones (120 mg/day for 3 years) on femoral neck BMD but only after regression analysis was done adjusting for multiple factors [21 ] . One of the two studies that used the highest dose of soy isoflavone was an open-label study on Taiwanese women that supplied isoflavones 100 or 200 mg/day and demonstrated significant changes in L1-L3 in the lower-dose isoflavone group, but no significant changes in the high-dose isoflavone group [24] . Bone turnover markers showed increased bone turnover, decreased bone formation, and increased resorption, contradicting the notion that isoflavone prevents bone loss. One study conducted on Japanese premenopausal and postmenopausal women that used 100 mg/day isoflavones found a 0.4% statistically significant increase in BMD but did not report which skeletal sites were measured [34] . The inclusion of premenopausal women adds a confounding factor, as premenopausal women have higher estrogen levels and slower rates of bone loss than postmenopausal women [35] . Consequently, premenopausal women may not respond to weak estrogenic interventions aimed at increasing BMD. A recently concluded 2-year clinical trial in US postmenopausal women that also provided high-dose soy isoflavones (200 mg/day) will determine effects on bone density and a marker of bone resorption [36] . 
Soy-enriched foods
Whereas Asian diets provide 50-150 mg of isoflavones daily, western diets do not usually include phytoestrogenrich foods. Therefore, to test whether isoflavones result in any health benefits, investigators have often supplemented western foods with isoflavones extracted from soy protein (Table 3 ) [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Studies have incorporated soy isoflavones into baked products such as breads and muffins, in snack and cereal bars, and into beverages such as drink mixes and soups.
All but one of the 13 studies were conducted on western women [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Most were randomized placebo-controlled trials that measured BMD and/or bone turnover markers and, except for one study that also enrolled women in premenopause, included only postmenopausal women aged 40-83 years. The majority of the trials were negative and there were no differences between the doses in the positive and negative studies. In the negative studies, the doses ranged from 60 to 130 mg isoflavone/ day with or without soy protein and the duration ranged from 3 months to 2 years [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . In one of these studies, participants were stratified according to whether they were able to produce equol or O-DMA (O-desmethylangolensin), both metabolites of the soy isoflavone daidzein. In O-DMA producers, there were nonsignificant increases in BMD in total, leg, and head BMD as compared to nonproducers. Total and site-specific BMD did not differ between equol producers and nonproducers even after adjusting for age [46] . In the three studies that showed positive results, the isoflavone doses ranged from 37.3 to 90 mg/day with a duration of 10 weeks to 1 year [47] [48] [49] .
Conclusion
Epidemiologic studies have shown a lower incidence of osteoporotic fractures, cardiovascular disease, postmenopausal symptoms, and some cancers in Asians compared to their western counterparts. Hip fracture is 50-60% less frequent among Asian compared to western women [50] , although this benefit gradually disappears as Asians adapt a western lifestyle [51] . Traditional Asian diets include varied amounts and types of soy foods. The beneficial effects of soy have been attributed to isoflavones, the estrogen-like compounds found in soy protein. These observations have led to the investigation of the relationship between the consumption of isoflavones and various health conditions. Although epidemiological studies suggest a positive association between the consumption of soy products and bone health in Asian women, clinical studies on western women testing soy foods or tablets containing isoflavones extracted from soy protein have had multiple limitations and have failed to demonstrate a consistent effect.
550 Parathyroids, bone, and mineral metabolism There was significant heterogeneity within the trials addressing soy isoflavone supplementation, not only in the amount and type of isoflavone supplemented and the form in which it was administered (whether it was natural soy, soy tablet, or soy-enriched food), but also in the participants' baseline BMD, skeletal site reported, and how the BMD measurements were reported. Results are contradictory and difficult to interpret and compare because of lack of standardization. One of the most salient problems was the high rates of attrition. However, compliance -assessed by either urinary or serum levels of isoflavone or counting the number of leftover powder packets or tablets -was usually good.
Two out of three recent meta-analyses of the effects of soy isoflavones on BMD reported positive findings only in lumbar spine BMD and one had negative results for all skeletal sites. However, these publications did not include the same trials [52] [53] [54] . The evidence on soy isoflavone supplementation has not yielded consistent answers in addressing whether they exert a protective effect on BMD. Although western women will likely continue to incorporate increasingly available soy products into their diets or supplements, it is unlikely that soy products will actually confer any protection from menopausal bone loss. This conflicting and mostly inconclusive evidence should be taken into account when considering using isoflavones for the prevention of bone loss and consequently fractures.
